Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test

NCT ID NCT07022574

Disease control Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This UCLA study is testing whether the Autoimmune Protocol (AIP) diet — which avoids dairy, grains, and sugar — can reduce protein levels in the urine of people with IgA nephropathy, a kidney disease that can lead to kidney failure. Thirty adults aged 18 to 65 with active disease will follow the diet for 6 months, tracking their urine protein daily and having monthly lab checks. The goal is to see if the diet can lower urine protein by 20% or more, which could help slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Autoimmune Protocol (AIP) diet — an anti-inflammatory eating plan that avoids dairy, grains, and sugar
What this could lead to
If the diet reduces urine protein by 20% or more, it could offer a simple way to slow kidney disease and delay the need for dialysis or other treatments.
What could go wrong
This is a small exploratory study with only 30 participants and no control group. Dietary changes can be hard to stick with, and results may not apply to everyone with IgA nephropathy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-65 * Diagnosed with IgA Nephropathy (IgAN) * Active disease with urine protein/creatinine ratio ≥ 1 * Stable ARB or ACE inhibitor for at least 1 month prior * GFR \> 30 * Not on Budesonide 1 month prior or during study Exclusion Criteria: * Inability to comply with dietary or follow-up requirements * Participation in other interventional studies * Significant comorbidities interfering with study participation -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IgA nephropathy (IGAN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis kidney disorder proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IgA nephropathy (IGAN)

Contacts and locations

Locations

  • UCLA

    Manhattan Beach, California, 90266, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.